This open enrollment, choose a plan that includes access to our world-class providers. Get better care now

Menu
Search

Award to UCSD to Fund Novel Approaches to Detecting Cancer

 

October 08, 2007  |  

Top-scoring award part of NIH initiative to detect cancer by targeting sugar molecules

The potential role of molecular glycans, or sugars, as biomarkers for the early detection of cancer will be the focus of a new research project at the University of California, San Diego (UCSD) School of Medicine, funded by a $2.3 million grant from the National Cancer Institute (NCI).

Ajit Varki, M.D., Distinguished Professor of Medicine and Cellular & Molecular Medicine at UC San Diego, and Richard Schwab, M.D., Assistant Professor at the Moores UCSD Cancer Center, will head a project focusing on the early diagnosis and prognosis of lung, pancreatic and ovarian cancers.  The NCI grant is part of a nation-wide initiative to develop new approaches to detecting and treating cancer through glycobiology – the study of the structure, biosynthesis and biology of complex sugar chains called glycans, found on the surfaces of all cells and many proteins in nature.  

Varki, the founder and co-director of UCSD’s Glycobiology Research and Training Center, is a pioneer in the field.   His research focuses on a family of sugars called the sialic acids, and their roles in biology, evolution and disease.  Schwab is a clinician-scientist with a special interest in the role of glycan antibodies in disease.

The UCSD project will target lung, pancreatic and ovarian cancers, which are associated with high mortality and very low five-year survival rates, according to Varki. The project seeks to expand on Varki’s research which shows that human cancers express glycans containing a non-human sialic acid called Neu5Gc.   When humans digest red meat or milk, this non-human sialic acid is selectively concentrated in the cancers, even while the body produces antibodies against these structures. 

“Despite many years of work by many investigators, there are no blood or urine markers that can reliably detect such cancers early enough in their course to make a difference in survival,” said Varki. “Our studies have unveiled a promising new approach to this problem, which takes advantage of the unusual propensity of human cancers to accumulate this non-human molecule from dietary sources and generate antibodies against it.”

Numerous studies comparing normal and tumor cells have shown that their glycan structures change with cancer development. Only recently have advances in technology allowed a systematic study of these structures.  In August, the NCI announced funding of seven Tumor Glycome Laboratories in the United States, including the UCSD project. Theirs was the top-ranked proposal from among the seven centers selected by NCI out of 29 applications.

Additional project researchers include Anup Datta, Ph.D., Director of the Glycotechnology Core Resource at UCSD, Yu-Tsueng Liu, Ph.D., project scientist at the Cancer Center, and Xi Chen, Ph.D., assistant professor of bioorganic chemistry at UC-Davis.

 ###

Media Contact: Debra Kain, 619-543-6163, ddkain@ucsd.edu


Related Specialties

UCSD Moores Cancer Center


Media Contact

Share This Article


Related News

11/14/2019
Researchers identified non-coding regions of the human genome that control the development and function of four brain cell types and mapped genetic risk variants for psychiatric diseases. They found t ...
11/13/2019
Researchers at University of California San Diego School of Medicine, as well as a diverse team of cardiologists and physicists, developed a machine learning algorithm to predict the life expectancy i ...
11/13/2019
UC San Diego researchers linked a gut bacteria toxin to worse clinical outcomes in patients with alcoholic liver disease, and discovered that treatment with bacteriophages clears the bacteria and elim ...
11/12/2019
National attention has been drawn to the plight of patients who have experienced the unintended side effects of prolonged ICU care such as memory loss and muscle weakness. Now, a research team led by ...



Follow Us